natgillin/translations-raw huggingface dataset:
As part of the marketing authorisation for rosuvastatin within Europe, AstraZeneca committed to apply for a 5-mg dose of rosuvastatin together with any necessary variations within 12 months of completion of the Mutual Recognition Process for the 10 mg, 20 mg and 40 mg formulations. 
Kot del dovoljenja za promet z rosuvastatinom znotraj Evrope, se je AstraZeneca obvezala, da bo v roku 12 mesecev po zaključku postopka za medsebojno priznavanje prijavila 5 miligramski odmerek rosuvastatina, skupaj z vsakršnimi potrebnimi variacijami,za odmerke z 10 mg, 20 mg in 40 mg.
During its April 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Crestor 5 mg or Crestor 10 mg as start dose. 
V toku sestanka aprila 2005, je bil CHMP glede na vse predložene podatke ter vse znanstvene diskusije z Odborom, mnenja, da je razmerje med koristmi in tveganji za zdravilo Crestor ugodno - in sicer v smislu, da naj bi bil začetni odmerek zdravila 5 ali 10 mg.
The approved use in The Netherlands was a 5 mg start dose for patients with predisposing factors to myopathy, and 10 mg as the recommended start dose for patients without these predisposing factors. 
5 mg za bolnike s predispozicijskimi dejavniki za miopatijo, ter 10 mg kot priporočeni začetni odmerek za bolnike brez teh dejavnikov.
This procedure started on 04 August 2004. 
Postopek se je priček 4. avgusta 2004.
Crestor (rosuvastatin calcium) is a selective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) that has been approved for use as a lipid-regulating agent in the management of patients with dyslipidaemia. 
metilglutaril koencima A (HMG-CoA) (statin), ki je bil odobren kot sredstvo za regulacijo lipidov pri zdravljenju bolnikov z dislipidemijo.
The issue was referred for arbitration by the UK on 1 November 2004 (day 89). 
Zadeva je bila dne 1. novembra 2004 (89.
Changes to SPC section 4.2 (Posology and method of administration) and 4.4 (Special warnings and special precautions for use) arising from the arbitration process were agreed by CHMP and a positive opinion was adopted on 21 April 2005. 
(Odmerjanje in način uporabe) ter 4.4 (Posebna opozorila in previdnostni ukrepi za uporabo) Povzetka glavnih značilnosti zdravila, ki izhajajo iz postopka obravnave.
A Marketing Authorisation for Crestor (10 to 40 mg) was originally granted to AstraZeneca in The 
Dovoljenje za promet z zdravilom za Crestor (10 do 40 mg) je bilo prvotno dodeljeno podjetju AstraZeneca na Nizozemskem, dne 6. novembra 2002, 7. decembra 2002 pa je bil sprožen postopek za medsebojno priznavanje.
Cancidas is used to treat the following infections in children, adolescents and adults: 
Zdravilo Cancidas se uporablja za zdravljenje naslednjih okužb pri otrocih, mladostnikih in odraslih:
Due to poor enrolment, the study was terminated early and only 51 patients were randomized. 
Zaradi slabe vključenosti je bila študija zgodaj zaključena in randomiziranih je bilo le 51 bolnikov.
Cancidas will always be prepared and given to you by a healthcare professional. 
Zdravilo Cancidas bo vedno pripravil in vam ga dal zdravstveni delavec.
• if you are allergic to caspofungin or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na kaspofungin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The mechanism of resistance has not been established. 
Mehanizma odpornosti še niso ugotovili.
If this occurs, caspofungin should be discontinued and appropriate treatment administered. 
Če se ta pojavi, je treba kaspofungin ukiniti in uporabiti ustrezno zdravljenje.
Do not use this medicine after the expiry date which is stated on the carton and the vial (the first two numbers are the month; the next four numbers are the year). 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na viali (prvi dve številki pomenita mesec, naslednje štiri pa leto).
This is because Cancidas can affect the way some other medicines work. 
To je zato, ker lahko zdravilo Cancidas vpliva na delovanje nekaterih drugih zdravil.
Date of first authorisation: 24 October 2001. 
Datum prve odobritve: 24. oktober 2001 Datum zadnjega podaljšanja: 07. september 2011
• you have ever had liver problems - you might need a different dose of this medicine 
• če ste kadar koli imeli težave z jetri - morda boste potrebovali drugačen odmerek tega zdravila.
Based on this study, no posology recommendations for neonates and infants can be made. 
Na podlagi te študije priporočil za odmerjanje pri novorojenčkih in dojenčkih ni mogoče podati.
This belongs to a group of medicines called antifungals. 
Spada v skupino zdravil, imenovanih antimikotiki.
N Engl J Med 1987 Oct 22;317(17):1098 (letter) 
N Engl J Med 1987 Oct 22;317(17):1098 (pismo)
The elimination of caspofungin from plasma is slow with a clearance of 10-12 ml/min. 
Izločanje kaspofungina iz plazme je počasno, očistek znaša 10-12 ml/min.
3 for 96 hours) and fever (>38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy. 
3 96 ur) in zvišano telesno temperaturo (> 38.0 °C), ki se nista odzivali na ≥ 96-urno parenteralno protibakterijsko terapijo.
Pharmacotherapeutic group: antimycotics for systemic use, ATC Code: J02AX04 
Farmakoterapevtska skupina: antimikotiki za sistemsko zdravljenje, oznaka ATC: J02AX04
Aseptically add 10.5 ml of water for injection. 
Aseptično dodajte 10,5 ml vode za injekcije.
Not Recommended 
Ne priporočamo.
Also some other medicines can affect the way Cancidas works. 
Prav tako lahko nekatera druga zdravila vplivajo na delovanje zdravila Cancidas.
Caspofungin resistance in Candida has been observed but the incidence may differ by species or region. 
Odpornost proti kaspofunginu pri Candidi so opazili, vendar se pojavnost odpornosti lahko razlikuje glede na vrsto ali območje.
DO NOT MIX OR CO-INFUSE CANCIDAS WITH ANY OTHER MEDICINES, as there are no data available on the compatibility of CANCIDAS with other intravenous substances, additives, or medicinal products. 
ZDRAVILA CANCIDAS NE MEŠAJTE IN NE INFUNDIRAJTE SKUPAJ S KATERIM KOLI DRUGIM ZDRAVILOM, ker ni podatkov o kompatibilnosti zdravila CANCIDAS in drugih substanc, aditivov in zdravil za intravensko uporabo.
You will be given Cancidas: 
Zdravilo Cancidas boste prejeli:
70 mg (from two 50 mg vials)** 
70 mg (iz dveh vial po 50 mg)**
The incidence of resistance to caspofungin by various clinical isolates of Aspergillus is rare. 
Pojavnost odpornosti proti kaspofunginu pri različnih kliničnih izolatih vrste Aspergillus je redka.
If you have been given more Cancidas than you should Your doctor will decide how much Cancidas you need and for how long each day. 
Če ste uporabili večji odmerek zdravila Cancidas, kot bi smeli Zdravnik se bo odločil, koliko zdravila Cancidas boste prejeli dnevno in trajanje zdravljenja.
Alternatively, the volume (ml) 
Druga možnost je, da količino (ml)
• Cancidas has not been studied in pregnant women. 
• Uporabe zdravila Cancidas pri nosečnicah niso preučevali.
What you need to know before you are given Cancidas 
Kaj morate vedeti, preden boste dobili zdravilo Cancidas
If you are worried that you may have been given too much Cancidas, tell your doctor or nurse straight away. 
Če pa vas skrbi, da ste morda dobili prevelik odmerek zdravila Cancidas, se takoj pogovorite z zdravnikom ali medicinsko sestro.
Other medicines and Cancidas 
Druga zdravila in zdravilo Cancidas
What Cancidas is and what it is used for What you need to know before you are given Cancidas How to use Cancidas 
Kaj je zdravilo Cancidas in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Cancidas Kako uporabljati zdravilo Cancidas Možni neželeni učinki
• cough, serious breathing difficulties - if you are an adult and have invasive aspergillosis you may be experiencing a serious respiratory problem that could result in respiratory failure. 
• kašelj, resne težave pri dihanju - če ste odrasli in imate invazivno aspergilozo, imate lahko resne težave z dihanjem, ki lahko povzročijo zastoj dihanja,
• phenytoin or carbamazepine (used for the treatment of seizures) 
• fenitoin ali karbamazepin (ki se uporabljata za zdravljenje napadov krčev)
Toxic epidermal necrolysis and StevensJohnson syndrome (see section 4.4) 
toksična epidermalna nekroliza in StevensJohnsonov sindrom (glejte poškodba kože poglavje 4.4)
INSTRUCTIONS FOR USE IN ADULT PATIENTS 
NAVODILA ZA UPORABO PRI ODRASLIH BOLNIKIH
Driving and using machines There is no information to suggest that Cancidas affects your ability to drive or operate machinery. 
Vpliv na sposobnost upravljanja vozil in strojev Ni podatkov, ki bi kazali, da zdravilo Cancidas vpliva na sposobnost vožnje ali upravljanja strojev.
Reported clinical and laboratory abnormalities among all adults treated with caspofungin (total 1,780) were typically mild and rarely led to discontinuation. 
Klinične in laboratorijske nepravilnosti, o katerih so poročali, so bile pri vseh odraslih, zdravljenih s kaspofunginom (skupno 1.780), po navadi blage in so le redko vodile v prekinitev zdravljenja.
In clinical studies, 1,865 adult individuals received single or multiple doses of caspofungin: 564 febrile neutropaenic patients (empirical therapy study), 382 patients with invasive candidiasis, 228 patients with invasive aspergillosis, 297 patients with localised Candida infections, and 394 individuals enrolled in Phase I studies. 
V kliničnih študijah je 1.865 odraslih oseb dobilo enkratne ali večkratne odmerke kaspofungina: 564 bolnikov s febrilno nevtropenijo (študija empiričnega zdravljenja), 382 bolnikov z invazivno kandidiazo, 228 bolnikov z invazivno aspergilozo, 297 bolnikov z lokaliziranimi okužbami s Candido in 394 oseb vključenih v študije I. faze.
• The active substance is caspofungin. 
• Učinkovina je kaspofungin.
The mechanism of resistance identified is FKS1 and/or FKS2 (for C. glabrata) gene mutations. 
Ugotovili so, da odpornost omogočijo mutacije na genih FKS1 in/ali FKS2 (pri C. glabrata).
The most frequent diagnoses were bloodstream infections (candidaemia) (77 %, n = 186) and Candida peritonitis (8 %, n = 19); patients with Candida endocarditis, osteomyelitis, or meningitis were excluded from this study. 
Najpogostejši diagnozi sta bili okužba krvi (kandidemija) (77 %, n = 186) in kandidiazni peritonitis (8 %, n = 19); bolniki s kandidiaznim endokarditisom, osteomielitisom ali meningitisom so bili iz študije izključeni.
Patients in the caspofungin group experienced breakthrough infections due to the following uncommon yeasts and moulds: Trichosporon species (1), Fusarium species (1), Mucor species (1), and Rhizopus species (1). 
Bolniki v kaspofunginski skupini so doživeli izbruh okužbe z naslednjimi redkimi vrstami kvasovk in plesni: Trichosporon (1), Fusarium (1), Mucor (1) in Rhizopus (1).
Do not use Cancidas 
Ne uporabljajte zdravila Cancidas
The following adverse reactions were reported during clinical studies and/or post-marketing use: System Organ 
V kliničnih študijah in/ali v obdobju trženja so poročali o naslednjih neželenih učinkih: Organski sistem Pogosti
The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate (as shown in the table below) to a 250 ml infusion bag or bottle. 
Raztopino za infundiranje pripravite tako, da ustrezno količino pripravljenega koncentrata (kot je prikazano v spodnji preglednici) aseptično dodate v 250 ml infuzijsko vrečko ali steklenico.
Caspofungin has in vitro activity against Aspergillus species (Aspergillus fumigatus [N = 75], Aspergillus flavus [N = 111], Aspergillus niger [N = 31], Aspergillus nidulans [N = 8], Aspergillus terreus [N = 52], and Aspergillus candidus [N = 3]). 
In vitro je kaspofungin učinkovit proti Aspergillus sp. (Aspergillus fumigatus n = 75, Aspergillus flavus n = 111, Aspergillus niger n = 31, Aspergillus nidulans n = 8, Aspergillus terreus n = 52 in Aspergillus candidus n = 3).
• Loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar level in the blood, low calcium level in the blood, increase calcium level in the blood, low magnesium level in the blood, increase in acid level in the blood 
• izguba apetita, povečanje količine telesne tekočine, porušeno ravnotežje soli v telesu, visoke vrednosti sladkorja v krvi, nizke vrednosti kalcija v krvi, zvišane vrednosti kalcija v krvi, nizke vrednosti magnezija v krvi, zvišane vrednosti kisline v krvi
Cancidas may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 
Zdravilo Cancidas lahko povzroči tudi resne kožne neželene učinke, kot npr. Stevens-Johnsonov sindrom (SJS) in toksično epidermalno nekrolizo (TEN).
Supplied in packs of 1 vial. 
Na voljo so škatle z 1 vialo.
What Cancidas is and what it is used for 
Kaj je zdravilo Cancidas in za kaj ga uporabljamo
Cancidas contains sucrose (a type of sugar). 
Zdravilo Cancidas vsebuje saharozo (vrsta sladkorja).
Intravenous use after reconstitution and dilution. 
Intravenska uporaba po predhodni pripravi in razredčenju.
• Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. 
• Empirično zdravljenje domnevnih glivnih okužb (npr. s Candido ali Aspergillusom) pri febrilnih, nevtropeničnih odraslih ali pediatričnih bolnikih.
Only a trained healthcare professional who has read the complete directions should prepare the medicine (please see below “Instructions of how to reconstitute and dilute Cancidas”). 
Zdravilo lahko pripravi le usposobljeni zdravstveni delavec, ki je prebral celotno navodilo (v nadaljevanju glejte "Navodilo za pripravo in razredčevanje zdravila Cancidas").
INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS 
NAVODILA ZA UPORABO PRI PEDIATRIČNIH BOLNIKIH
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands or 
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Nizozemska ali
Caspofungin also has in vitro activity against Candida species (Candida albicans [N = 1,032], Candida dubliniensis [N = 100], Candida glabrata [N = 151], Candida guilliermondii [N = 67], Candida kefyr [N = 62], Candida krusei [N = 147], Candida lipolytica [N = 20], Candida lusitaniae [N = 80], Candida parapsilosis [N = 215], Candida rugosa [N = 1], and Candida tropicalis [N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine. 
In vitro je kaspofungin učinkovit tudi proti Candida sp. (Candida albicans n = 1.032, Candida dubliniensis n = 100, Candida glabrata n = 151, Candida guilliermondii n = 67, Candida kefyr n = 62, Candida krusei n = 147, Candida lipolytica n = 20, Candida lusitaniae n = 80, Candida parapsilosis n = 215, Candida rugosa n = 1 in Candida tropicalis n = 258, vključno z izolati s prenosnimi mutacijami, ki so odgovorne za odpornost proti številnim antibiotikom, in tistimi s pridobljeno ali intrinzično odpornostjo proti flukonazolu, amfotericinu B in 5-flucitozinu.
* 10.5 ml should be used for reconstitution of all vials. 
*Za rekonstitucijo vseh vial je treba uporabiti 10,5 ml vehikla.
Your doctor will determine the duration of your treatment and how much Cancidas you will be given each day. 
Zdravnik bo določil trajanje zdravljenja in dnevni odmerek zdravila Cancidas.
Cancidas makes fungal cells fragile and stops the fungus from growing properly. 
Zdravilo Cancidas povzroča krhkost glivnih celic in ustavi pravilno rast gliv.
In a double-blind, randomized (2:1) comparator-controlled study safety, tolerability and efficacy of caspofungin (2 mg/kg/d intravenously, infused over 2 hours) vs amphotericin B deoxycholate (1 mg/kg/d) was evaluated in neonates and infants less than 3 months of age with (culture-confirmed) invasive candidiasis. 
V dvojno slepi, randomizirani (2:1), primerjalni nadzorovani študiji so ocenjevali varnost, prenašanje in učinkovitost kaspofungina (2 mg/kg/dan intravensko, infundiran v 2 urah) v primerjavi z amfotericin B deoksiholatom (1 mg/kg/dan) pri novorojenčkih in dojenčkih, mlajših od 3 mesecev, z invazivno kandidiazo (potrjena kultura).
The overall success rates in the MITT analysis results, adjusted by risk strata, were as follows: 46.6 % (26/56) for caspofungin and 32.2 % (8/25) for liposomal amphotericin B. 
Celotna deleža uspeha po rezultatih MITT analize, prilagojenih glede na stratume tveganja, sta bila: 46,6 % (26/56) za kaspofungin in 32,2 % (8/25) za liposomski amfotericin B.
Isolates of Candida with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin >2 mg/L (4- to 30-fold MIC increases) have been reported using standardized MIC testing techniques approved by the CLSI). 
Pri manjšem številu bolnikov so med zdravljenjem odkrili izolate vrste Candida z zmanjšano občutljivostjo za kaspofungin (poročali so o MIC za kaspofungin > 2 mg/l (4-do 30-kratno povečanje MIC), pri čemer so uporabili standardizirane tehnike za testiranje MIC, odobrene s strani CLSI).
Equilibrate the refrigerated vial of CANCIDAS to room temperature. 
Pustite, da se ohlajena viala z zdravilom CANCIDAS ogreje na sobno temperaturo.
However, variability was seen in both C1 hr (Day 4 geometric mean 11.73 µg/ml, range 2.63 to 22.05 µg/ml) and C24 hr (Day 4 geometric mean 3.55 µg/ml, range 0.13 to 7.17 µg/ml). 
Vendar pa je bila variabilnost opazna tako pri C1 h (geometrična sredina 4. dan 11,73 µg/ml, razpon od 2,63 do 22,05 µg/ml) kot pri C24 h (geometrična sredina 4. dan 3,55 µg/ml, razpon od 0,13 do 7,17 µg/ml).
For adult patients with mild hepatic impairment (Child-Pugh score 5 to 6), no dosage adjustment is needed. 
Pri odraslih bolnikih z blago jetrno okvaro (stopnja Child-Pugh 5 do 6 točk) prilagoditev odmerka ni potrebna.
The proportion of patients with fungal-free survival at 2 weeks post-therapy in the caspofungin treatment group (71.0 %) was similar to that seen in the amphotericin B deoxycholate treatment group (68.8 %). 
Delež bolnikov s preživetjem brez gliv pri 2 tednih po zdravljenju je bil v skupini, ki je prejemala kaspofungin (71,0 %), podoben kot v skupini z amfotericin B deoksiholatom (68,8 %).
Standard preparation (reconstituted CANCIDAS added to 250 ml) final concentration 
Standardna priprava (koncentrat zdravila CANCIDAS dodan v 250 ml) končna koncentracija
What Cancidas looks like and contents of the pack Cancidas is a sterile, white to off-white compact powder. 
Izgled zdravila Cancidas in vsebina pakiranja Zdravilo Cancidas je sterilen, bel do skoraj bel, kompakten prašek.
Talk to your doctor, nurse or pharmacist before you are given Cancidas if: 
Posvetujte se z zdravnikom, medicinsko sestro ali farmacevtom, preden dobite zdravilo Cancidas:
• Sensation of fast or irregular heartbeats, rapid heartbeat, irregular heartbeat, abnormal heart rhythm, heart failure 
• občutek hitrega ali nepravilnega utripanja srca, pospešen srčni utrip, nepravilen srčni utrip, nenormalni srčni ritem, srčno popuščanje
To reconstitute the powder, bring the vial to room temperature and aseptically add 10.5 ml of water for injection. 
Za pripravo koncentrata prenesite vialo na sobno temperaturo in vanjo aseptično dodajte 10,5 ml vode za injekcije.
**If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials. 
**Če viale po 70 mg ni na voljo, lahko odmerek 70 mg pripravimo iz dveh vial po 50 mg.
Renal impairment: In a clinical study of single 70 mg doses, caspofungin pharmacokinetics were similar in adult volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and control subjects. 
Okvara ledvic: V klinični študiji enkratnih 70 mg odmerkov je bila farmakokinetika kaspofungina pri odraslih prostovoljcih z blago ledvično okvaro (kreatininski očistek 50 do 80 ml/min) podobna kot pri kontrolnih preiskovancih.
• Women given Cancidas should not breast-feed. 
• Ženske, ki uporabljajo zdravilo Cancidas, ne smejo dojiti.
Susceptibility testing was performed according to a modification of both the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards [NCCLS]) method M38-A2 (for Aspergillus species) and method M27-A3 (for Candida species). 
Testiranje občutljivosti je bilo izvedeno po modifikaciji metode M38A2 (za Aspergillus sp.) kot tudi metode M27-A3 (za Candida sp.) Inštituta za klinične in laboratorijske standarde (CLSI, prej znanega pod imenom Nacionalni odbor za klinične laboratorijske standarde [National Committee for Clinical Laboratory Standard - NCCLS]).
Stability data have shown that the concentrate for solution for infusion can be stored for up to 24 hours when the vial is stored at 25°C or less and reconstituted with water for injection. 
Stabilnostni podatki kažejo, da koncentrat za pripravo raztopine za infundiranje, ki smo ga pripravili z vodo za injekcije, lahko shranjujemo do 24 ur pri temperaturi 25 °C ali manj.
b This will give a final caspofungin concentration in the vial of 
b Končna koncentracija kaspofungina v viali bo tako
Instructions of how to reconstitute and dilute CANCIDAS: 
Navodilo za pripravo in razredčevanje zdravila CANCIDAS:
In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed. 
V omejenih kliničnih izkušnjah so pri bolnikih z invazivno aspergilozo opazili odpornost proti kaspofunginu.
The favourable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81 % (30/37) in invasive candidiasis, 50 % (5/10) in invasive aspergillosis, and 100 % (1/1) in oesophageal candidiasis. 
Deleži ugodnega odziva za posamezno indikacijo so bili na koncu zdravljenja s kaspofunginom v analizi MITT naslednji: 81 % (30/37) pri invazivni kandidiazi, 50 % (5/10) pri invazivni aspergilozi in 100 % (1/1) pri ezofagealni kandidiazi.
If any of the above applies to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given Cancidas. 
Če kaj od zgoraj naštetega velja za vas (ali pa niste prepričani), se pogovorite z zdravnikom, medicinsko sestro ali farmacevtom, preden dobite zdravilo Cancidas.
How Cancidas works 
Kako zdravilo Cancidas deluje
Unopened vials: store in a refrigerator (2°C - 8°C). 
Neodprte viale: shranjujte v hladilniku (2 C - 8 C).
For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), caspofungin 35 mg daily is recommended based upon pharmacokinetic data. 
Pri odraslih bolnikih z zmerno jetrno okvaro (stopnja Child-Pugh 7 do 9 točk) glede na farmakokinetične podatke priporočamo kaspofungin v odmerku 35 mg dnevno.
CANCIDAS contains no preservatives. 
Zdravilo CANCIDAS ne vsebuje konzervansov.
• Itching at the injection site. 
• srbenje na mestu injiciranja
Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (<500 cells/mm 
Za študijo ustrezni bolniki so dobivali kemoterapijo zaradi malignoma ali so prestali presaditev hematopoetskih matičnih celic ter so imeli nevtropenijo (< 500 celic/mm
Moderate (creatinine clearance 31 to 49 ml/min), advanced (creatinine clearance 5 to 30 ml/min), and end-stage (creatinine clearance <10 ml/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49 % for AUC). 
Zaradi zmerne okvare (kreatininski očistek 31 do 49 ml/min), napredovale okvare (kreatininski očistek 5 do 30 ml/min) in končne ledvične odpovedi (kreatininski očistek < 10 ml/min in na dializi) se je plazemska koncentracija kaspofungina po enem odmerku zmerno povečala (razpon: za 30 do 49 % AUC).
Laboratories Merck Sharp & Dohme- Chibret, Route de Marsat-RIOM, 63963 Clermont-Ferrand Cedex 9, France 
Laboratories Merck Sharp & Dohme- Chibret, Route de Marsat-RIOM, 63963 Clermont-Ferrand Cedex 9, Francija
Renal impairment No dosage adjustment is necessary based on renal impairment (see section 5.2). 
Okvara ledvic Prilagoditev odmerka glede na ledvično okvaro ni potrebna (glejte poglavje 5.2).